Y90 Radioembolization

FINAL (2)-150.png
BackTABLEfinal-2tone_edited.png

© 2020 by Backtable. All rights reserved.

Disclaimer: The Materials available on BackTable.com are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients.

Overview

Overview content for Y90 Radioembolization is not yet available.

Pre-Procedure

Devices:
• Resin - SIR-Spheres (Sirtex)
• Sphere diameter between 20-60 μm
• Lower activity per sphere compared to glass
• Glass - Therasphere (BTG)
• Mean sphere diameter 25 μm
• Higher activity per sphere compared to resin

Indications:
• Primary and secondary hepatic malignancies
• Hepatocellular carcinoma (HCC)
• Cholangiocarcinoma
• Metastatic colorectal (mCRC)
• metastatic neuroendocrine (mNET)
• Potential applications for metastatic tumors: breast, melanoma, and renal cell

Contraindications:
• Poor performance status, ECOG >2
• Extensive extrahepatic disease
• Hepatopulmonary shunting with expected dose to lungs > 30-Gy
• Active hepatic infection
• Pregnancy
• Poor liver function - depends on degree of liver dysfunction and amount of liver being treated. Considerations for liver dysfunction include:
• Extensive hepatic tumor involvement
• Child-Pugh C
• Hepatic encephalopathy and uncontrolled ascites
• Total bilirubin >2 mg/dl, INR > 2.0

Initial Steps:
• Consult with H&P
• Oncologic pathology and staging
• Performance status
• Prior chemotherapy, locoregional therapy and surgery
• Labs: liver function, coagulation, renal function and tumor markers
• Review/Order preprocedural imaging
• Evaluate tumor burden and potential liver segments involved
• Arterial supply to liver. Look for variant anatomy and potential arteries which predispose patient to non-target embolization
• Portal vein patency

Medications:
• Moderate sedation: consider using minimal sedation for mapping as high quality angiography depends on patient complying with multiple breath hold maneuvers.

For y90 treatment procedure
• Premedications vary between institutions and operators
• Consider: 10 mg Dexamethasone, 4-8 mg Zofran
• Somatostatin analogs for mNET - 500 mcg of octreotide SC
• Antibiotics: at discretion of operator for low risk patients
• Some institutions treat with ciprofloxacin if cystic duct embolization is expected
• Moxifloxacin recommended in patients with incompetent/absent sphincter of oddi

Procedure

Mapping procedure
Arterial access, sheath placement, 5 or 6-Fr
Recommended all angiography performed with power injector and breath hold maneuvers. Goal is to clearly define hepatic arterial anatomy, delineate tumor vascular supply and identify extrahepatic vessels at risk for nontarget embolization.
Suggested injection rates are in italics and should be modified based on anatomy, equipment and operator preferences.
SMA (3 ml/s for 18 seconds)
Carry run out to portal phase to confirm patency
Celiac artery (4 ml/s for 12 seconds)
Left gastric artery (1 ml/s for 6 seconds)
Not always necessary
If using Sos to access celiac, apply back tension to catheter until catheter points cephalad. With catheter directed superiorly, usually possible to direct the microcatheter into the left gastric.
Sometimes easier to access the right gastric retrograde via left gastric. Need continuous anastomosis between the two vessels
Common hepatic artery (3 ml/s for 12 seconds)
Gastroduodenal artery (2 ml/s for 8 seconds)
evaluate for accessory vessels and
parasitization of flow to liver
Proper hepatic artery (3 ml/s for 12 seconds)
Good opportunity to identify the right gastric artery
Left hepatic artery (2 ml/s for 8 seconds)
Right hepatic artery (2 ml/s for 10 seconds)
Vessels which may result in nontarget embolization
Injecting MAA and treating distal to takeoff may be best approach
If possible to catheterize, coil embolize vessels
Potential vessels include: GDA, right gastric, supraduodenal, falciform, left phrenic, gastroesophageal branch, left gastric
Infuse 99mTc-MAA from the expected treatment locations
4 to 5 mCi of 99mTc-MAA
Can split amounts if treating from multiple locations
Safer to have nuclear medicine split the MAA doses before doses are called to cath lab
Strongly consider the routine use of cone-beam CT in available
Good to identify potential sites of non-target embolization
Can more accurately delineate the volume and segments of liver which will receive treatment

Y90 administration procedure
• Arterial access, sheath placement, 5 or 6-Fr
• Repeat diagnostic angiography from appropriate positions.
• Place microcatheter at expected treatment location, same location MAA was administered from
• Repeat diagnostic angiography to confirm appropriate and safe position
• Administer radioembolic
• Remove microcatheter and endhole catheter with radiation precautions.
• Dispose of catheters and glove in appropriate containers.

Post-Procedure

Postprocedure Care
• Monitor patient 1-6 hours after mapping & treatment
• Recovery time primarily driven by radial or femoral access precautions
• Discharge patient same day
• Home care
• Mapping procedure: typically no pain medications or antiemetics needed
• Treatment procedure:
• Adequate pain control: usually narcotic not neccessary
• Antiemetics PRN - Ondastetron 4-8 mg
• Protonix (pantoprazole) - may reduce gastrointestinal irritation. Can initiate at time of mapping and continue 1 month after the final treatment session
• Avoid medications with acetaminophen

Follow-up and Outcome Assessment:
• After final treatment session, 1 month clinic visit with labs to assess liver function.
• Assess energy level and reassess ECOG
• Pain palliation response
• LFTs and tumor markers - calculate Child-Pugh score

Tumor markers:
• Radiologic response will vary from institution and provider - consider standardization within your institution
• Consider 1 month CT/MRI: may not reflect treatment changes this early. Interpret with caution as there can be paradoxical increase in tumor size related to hemorrhage, edema and necrosis.
• Consider follow up at 3-6 month intervals after treatment
• CT vs MRI: varies from institution. Keep consistent from pretreatment to postprocedure
• mRECIST guidelines and EASL for enhancing tumors like HCC
• RECIST for solid tumors

Complications:
• Radioembolization-induced liver disease (REILD): 0-4% of patients
• Spectrum of liver dysfunction which can progress to hepatic failure
• Typically occurs 1-2 months post treatment
• Patients present with jaundice and ascites with increased bilirubin and LFTs. Absence of tumor progression or biliary obstruction.
• Treat with high dose steroids
• Radiation pneumonitis: <1%
• Radiation cholecystitis: attempt to embolize distal to origin of cystic artery if possible
• Consider prophylactic ciprofloxacin if gallbladder is within the radiation field.
• Antibiotics, hydration and pain control. Few may require cholecystectomy or cholecystostomy
• GI ulcers: <5%
• Can result from nontarget embolization of GDA, right/left gastric or supraduodenal arteries
• Present hours to days after delivery: abdominal pain, nausea, vomiting and possible GI bleed
• Should confirm GI ulceration with endoscopy
• Treatment to include protonix, sucralfate, pentoxifylline and vitamin E. Some may need surgery.
• Postembolization syndrome: abdominal pain, low-grade fever, nausea, vomiting, malaise within 1 week of treatment
• Other: hepatic abscess, pancreatitis and bile duct injury/biloma,

Related Procedures

No related procedures.

Step-by-step guidance on how to perform Liver Ablation. Review tools, techniques, pearls, and pitfalls on the BackTable Web App.
Step-by-step guidance on how to perform Portal Vein Embolization. Review tools, techniques, pearls, and pitfalls on the BackTable Web App.
Step-by-step guidance on how to perform Radial Access. Review tools, techniques, pearls, and pitfalls on the BackTable Web App.
Step-by-step guidance on how to perform Transarterial Chemoembolization. Review tools, techniques, pearls, and pitfalls on the BackTable Web App.
 

References

[1] BackTable, LLC (Producer). (2017, November 5). Ep 16 – Pressure-Directed Therapy in Y90 [Audio podcast]. Retrieved from https://www.backtable.com/podcasts
[2] Salem, R., Lewandowski, R. J., Sato, K. T., Atassi, B., Ryu, R. K., Ibrahim, S., … Murthy, R. (2007). Technical Aspects of Radioembolization with90Y Microspheres. Techniques in Vascular and Interventional Radiology, 10(1), 12–29. http://doi.org/10.1053/j.tvir.2007.08.001
[3] Padia SA, Lewandowski RJ, Johnson GE, et al. Radioembolization of Hepatic Malignancies: Background, Quality Improvement Guidelines, and Future Directions. J Vasc Interv Radiol. 2017;28(1):1-15.
[4] Gaba RC. Planning Arteriography for Yttrium-90 Microsphere Radioembolization. Semin Intervent Radiol. 2015;32(4):428-38.
[5] Joo I, Kim HC, Kim GM, Paeng JC. Imaging Evaluation Following Y Radioembolization of Liver Tumors: What Radiologists Should Know. Korean J Radiol. 2018;19(2):209-222.
[6] Salem R, Lewandowski RJ, Sato KT, et al. Technical aspects of radioembolization with 90Y microspheres. Tech Vasc Interv Radiol. 2007;10(1):12-29.

Join The Discussion

 

Demos

Demos are not yet available for this procedure.

Please check back soon.

Spheres vs. Chemoembolization vs. Bland embolization by Dr. Charles Nutting

This demo description is not yet available.

Transradial Angiography and Embolization prior to Y-90 Radioembolization

At Mount Sinai Hospital in New York City, Interventional Radiologists, Dr. Aaron Fischman, Dr. Scott Nowakowski and Dr. Gajan Sivananthan perform transradial access for mapping angiography and coil embolization prior to Y-90 radioembolization of colon cancer liver metastasis in a patient with aortic dissection.

Cone Beam CT and Mapping Angiography Prior to Y-90 Radioembolization using a Transradial Approach

Interventional Radiologists Dr. Edward Kim, Dr. Rahul Patel, and Dr. Mustafa Syed perform mapping angiography and cone beam CT(CBCT) prior to SIRT radioembolization in a patient with metastatic neuroendocrine tumor to the liver using a transracial approach at Mount Sinai Hospital in New York City.

Transradial Angiography and Mapping Prior to Radioembolization and Coil Embolization of GDA

At Mount Sinai Hospital in New York City, Interventional Radiologists Dr. Aaron Fischman, Dr. Scott Nowakowski and Dr. Vinit Amin perform a mapping procedure prior to SIRT radioembolization in a fully anticoagulated patient with metastatic #ovarian carcinoma to the liver using a #transradial approach.

Radioembolization of Liver Metastases by Dr. Florian Wolf

Key steps of a radioembolization procedure in a patient with liver metastases.

 

Tools

Tools are not yet available for this procedure.

Please check back soon.

DAVYR 3 Y90 Dosimetry

DAVYR 3 Y90 Dosimetry on BackTable

Mathematical modeling tool designed to provide the user with a more clear understanding of the relationship between activity (GBq) determination, and compartmental dose (liver, tumor, lung) as relating to Trans-Arterial Radioembolization (TARE) with Yttrium-90 microspheres.

Child-Pugh Score Calculator

Child-Pugh Score Calculator on BackTable

Estimate cirrhosis severity with this quick Child-Pugh Score calculator.

 

Literature

Literature is not yet available for this procedure.

Please check back soon.

American Journal of Roentgenology (Nov 2016)

Transradial Approach for Hepatic Radioembolization: Initial Results and Technique

The transradial approach (TRA) has been shown to reduce the morbidity and mortality associated with arterial coronary interventions. Selective internal radiation therapy (SIRT) performed via the TRA can enhance patient comfort, compared with the traditional transfemoral approach (TFA), by allowing immediate ambulation and precluding potential complications associated with the TFA, such as closure device injury or retroperitoneal hematoma. We report our initial experience with and technique for using the TRA for SIRT.

American Journal of Roentgenology (Dec 2014)

Survival Efficacy and Safety of Small Versus Large Doxorubicin Drug-Eluting Beads TACE Chemoembolization in Patients with Unresectable HCC

The purpose of this study was to investigate the overall survival, efficacy, and safety of small (100–300 μm) versus large (300–500 and 500–700 μm) doxorubicin drugeluting beads transarterial chemoembolization (DEB TACE) in patients with unresectable hepatocellular carcinoma (HCC).

CardioVascular and Interventional Radiology (Feb 2010)

Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study.

This article description is not yet available.

CardioVascular and Interventional Radiology (Jul 2007)

Radioembolization With Y90 Microspheres: Angiographic and Technical Considerations

The purpose of this review is to provide a thorough discussion and detailed presentation of the angiographic and technical aspects of radioembolization.

Seminars in Interventional Radiology (Dec 2015)

Planning Arteriography for Yttrium-90 Microsphere Radioembolization

This article aims to present a simple overview of a single operator’s technical approach to planning arteriography performed prior to Y90 Radioembolization — including tips, tricks, and pitfalls—based on experience gained in having performed hundreds of hepatic arteriography procedures.

Journal of Clinical Oncology (May 2016)

SIRFLOX Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients with Metastatic Colorectal Cancer

This article description is not yet available.

 

Podcasts

Podcasts are not yet available for this procedure.

Please check back soon.

Interventional Oncology in Private Practice (Part 2) BackTable Podcast Guest Dr. Justin Lee

Dr. Justin Lee

Dr. Christopher Beck

Interventional Radiologist Justin Lee tells us about his approach to treatment of Hepatocellular Carcinoma (HCC), including how this has changed over his years in private practice.

&

Locoregional Therapies for Bridging to Transplant in HCC BackTable Podcast Guest Dr. Alex Kim

Dr. Alex Kim

Dr. Christopher Beck

Interventional Radiologist Dr. Alex Kim and Dr. Christopher Beck discuss the utility of different locoregional liver therapies in bridging HCC patients to transplant.

&

&

Interventional Oncology in Private Practice (Part 1) BackTable Podcast Guest Dr. Justin Lee

Dr. Justin Lee

Dr. Christopher Beck

Interventional Radiologist Justin Lee tells us how he started from scratch in growing a robust Interventional Oncology program in private practice, including pitfalls to avoid.

&

Pressure-Directed Therapy in Y90 Podcast Guest Dr. Nainesh Parikh

Dr. Charles Nutting

Dr. Nainesh Parikh

The docs discuss pressure-directed, antireflux infusion for Y90 Radioembolization, including the SureFire Infusion system.

&

HCC Bridge to Liver Transplant Podcast Guest Dr. Jennifer Berumen

Dr. Jennifer Berumen

Dr. Isabel Newton

Transplant Surgeon Dr. Jennifer Berumen and Interventional Radiologist Dr. Isabel Newton discuss the treatment of HCC and bridging patients to successful liver transplantation.

&

 

Blog Articles

Blog articles are not yet available for this procedure.

Please check back soon.

bt-procedure-feed-arterial-revasculariza

Procedure Kit For Pressure Directed Therapy in Y90 Radioembolization of HCC

Our interventional radiologist guests cover what tools you need to get started with pressure directed therapy in Y90 radioembolization; as well as different ...

bt-procedure-feed-arterial-revasculariza

Pressure-Directed Therapy for the Treatment of Hepatocellular Carcinoma (HCC)

Hepatocellular carcinoma is the third leading cause of cancer-related deaths. Treatment options for HCC depend on extent of disease, severity of underlying l...

bt-procedure-feed-arterial-revasculariza

Principles of Pressure Directed Therapy with Y90 Radioembolization in Hepatocellular Carcinoma (HCC)

In our first podcast on pressure directed therapy, Dr. Charles Nutting and Dr. Nainesh Parikh discuss some of the first principles of Y90 radioembolization d...

bt-procedure-feed-arterial-revasculariza

TACE Versus Radioablation in the Treatment of Hepatocellular Carcinoma (HCC)

Transarterial chemoembolization (TACE) and radioembolization (Y90) have individualized roles in the treatment of hepatocellular carcinoma. Dr. Justin Lee and...

bt-procedure-feed-arterial-revasculariza

When To Use Pressure Directed Devices with Y90 Radioembolization in Hepatocellular Carcinoma (HCC)

When treating unresectable HCC with Y90 radioembolization, pressure directed devices may have distinct technical advantages over end-hole catheters in some c...